We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer

By LabMedica International staff writers
Posted on 16 Dec 2025

Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. More...

Monitoring these cancers for recurrence or relapse typically relies on tissue biopsies, which are painful, invasive, and not well-suited for repeated follow-up. This creates a major clinical challenge, particularly for long-term surveillance and early detection of relapse. Now, a new study has shown that molecular signals linked to tumor activity can be captured from simple saliva and blood samples, offering a non-invasive alternative to repeated biopsies.

In the study conducted at Griffith University (Queensland, Australia), researchers demonstrated that tumor-related molecular signatures can be reliably detected in small extracellular vesicles found in plasma and saliva, closely reflecting the biological profile of head and neck tumors. The study focused on small extracellular vesicles, nanoscale particles released by cells that carry proteins and other molecular cargo linked to cellular behavior.

Investigators examined whether vesicles isolated from patient plasma and saliva mirrored those released directly by tumor tissue. By comparing tumor-derived vesicles with those isolated from biofluids, the team analyzed overlap in protein cargo and functional relevance. They found substantial similarity between tumor vesicles and those in saliva and plasma, indicating that biofluids capture key aspects of tumor biology.

This approach allows tumor monitoring without direct access to tumor tissue. The findings, published in the journal View, showed that more than 60 percent of identified proteins were shared across tumor, plasma, and saliva vesicles. Several of these proteins are known to play roles in tumor progression, immune system modulation, and extracellular matrix remodeling. Their consistent presence across all sample types highlights their diagnostic and biological significance.

These results suggest that saliva and blood-based vesicle analysis could be used for early detection of recurrence, longitudinal disease monitoring, and biomarker-driven treatment decisions. This non-invasive strategy could enable more frequent testing, earlier clinical intervention, and improved personalization of care for patients with head and neck cancers.

Future work will focus on refining extracellular vesicle–based biomarker panels and validating their clinical utility in larger patient cohorts. Researchers also plan to study the functional roles of the overlapping proteins to better understand how they contribute to tumor progression and metastasis.

“This study lays the groundwork for developing clinically applicable EV-based biomarker panels which can be used in routine diagnostic testing,” said Research Fellow Abolfazl Jangholi, first author of the study. “By investigating the functional roles of the overlapping proteins, we can uncover how these molecules contribute to tumor progression and metastasis.”

Related Links:
Griffith University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.